157 related articles for article (PubMed ID: 32073902)
21. Development and dosimetry of
Dos Santos JC; Schäfer M; Bauder-Wüst U; Lehnert W; Leotta K; Morgenstern A; Kopka K; Haberkorn U; Mier W; Kratochwil C
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1081-1091. PubMed ID: 30603987
[TBL] [Abstract][Full Text] [Related]
22. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
[TBL] [Abstract][Full Text] [Related]
23. The possible role of insulin-like growth factor-1 in osteosarcoma.
Li YS; Liu Q; He HB; Luo W
Curr Probl Cancer; 2019 Jun; 43(3):228-235. PubMed ID: 30217668
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
25. [
Yang Y; Alencar LMR; Pijeira MSO; Batista BDS; França ARS; Rates ERD; Lima RC; Gemini-Piperni S; Santos-Oliveira R
Drug Deliv; 2022 Dec; 29(1):186-191. PubMed ID: 35191342
[TBL] [Abstract][Full Text] [Related]
26. Antitumor Activity of Novel Bone-seeking, α-emitting
Juzeniene A; Bernoulli J; Suominen M; Halleen J; Larsen RH
Anticancer Res; 2018 Apr; 38(4):1947-1955. PubMed ID: 29599310
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
28. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
29. Clinical Applications of Nanosized Drug-Delivery Systems in Lung Cancer Imaging and Therapy.
Karpuz M; Silindir-Gunay M; Ozer AY
Crit Rev Ther Drug Carrier Syst; 2020; 37(5):435-471. PubMed ID: 33389847
[TBL] [Abstract][Full Text] [Related]
30. Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.
Fernandes I; Melo-Alvim C; Lopes-Brás R; Esperança-Martins M; Costa L
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467481
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma.
Maniscalco L; Iussich S; Morello E; Martano M; Gattino F; Miretti S; Biolatti B; Accornero P; Martignani E; Sánchez-Céspedes R; Buracco P; De Maria R
Vet J; 2015 Aug; 205(2):272-80. PubMed ID: 25257352
[TBL] [Abstract][Full Text] [Related]
32. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.
Blattmann C; Oertel S; Schulz-Ertner D; Rieken S; Haufe S; Ewerbeck V; Unterberg A; Karapanagiotou-Schenkel I; Combs SE; Nikoghosyan A; Bischof M; Jäkel O; Huber P; Kulozik AE; Debus J
BMC Cancer; 2010 Mar; 10():96. PubMed ID: 20226028
[TBL] [Abstract][Full Text] [Related]
33. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
34. ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells.
Roundhill EA; Jabri S; Burchill SA
Cancer Lett; 2019 Jul; 453():142-157. PubMed ID: 30910588
[TBL] [Abstract][Full Text] [Related]
35. Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
Gorlick R; Huvos AG; Heller G; Aledo A; Beardsley GP; Healey JH; Meyers PA
J Clin Oncol; 1999 Sep; 17(9):2781-8. PubMed ID: 10561353
[TBL] [Abstract][Full Text] [Related]
36. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
[TBL] [Abstract][Full Text] [Related]
37. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
38. Radionuclide Therapy of Metastatic Prostate Cancer.
Kratochwil C; Haberkorn U; Giesel FL
Semin Nucl Med; 2019 Jul; 49(4):313-325. PubMed ID: 31227054
[TBL] [Abstract][Full Text] [Related]
39. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
[TBL] [Abstract][Full Text] [Related]
40. Childhood multifocal osteosarcoma. Clinicopathologic and radiologic correlates.
Parham DM; Pratt CB; Parvey LS; Webber BL; Champion J
Cancer; 1985 Jun; 55(11):2653-8. PubMed ID: 3857959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
